Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung

---

Copy For Citation

Özgençli I., BUDAK H., Ciftci M., Anar M.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.18, no.11, pp.1599-1605, 2018 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 18 Issue: 11
• Publication Date: 2018
• Doi Number: 10.2174/1871520618666180525095520
• Journal Name: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1599-1605
• Keywords: Thioredoxin reductase, cancer, rat lung, lichen acid, inhibition, mitochondrial TrxR.f, USNIC ACID, SECONDARY METABOLITES, MAMMALIAN THIOREDOXIN, HYPOGYMNIA-PHYSODES, LIVER THIOREDOXIN, MAJOR METABOLITES, DIFFRACTAIC ACID, CELL-LINES, ANTIOXIDANT, PURIFICATION
• Ataturk University Affiliated: Yes

Abstract

Background: Thioredoxin reductase (E.C 1.6.4.5.; TrxR) is a widely distributed flavoprotein that catalyzes the NAI)PH-dependent reduction of thioredoxin (Trx) in many cellular events such as DNA synthesis. DNA repair, angiogenesis, antioxidative defense, and regulating apoptosis. Although TrxR is indispensible in protecting cells against oxidative stress, the overexpression of TrxR is seen in many aggressive tumors. Therefore, targeted inhibition of TrxR has been accepted as a new approach for chemotherapy.